drugset
drugset / Trial / NCT04926051

A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption

NCT04926051 ↗

Phase 1 Completed 40 enrolled Bristol-Myers Squibb
RandomizedSequentialQuadruple-blindBasic science

Summary

The purpose of this study is to evaluate the safety, tolerability and drug levels of BMS-986172 and evaluate the effects of food on BMS-986172 absorption.

Timeline

Start
2021-06-15
Primary completion
2021-12-28
Completion
2021-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986172 Small molecule — —

Indications

No indication recorded.